Comparing 6 and 3 rounds of chemotherapy before surgery for thymus tumors
Compares 6 and 3 chemotherapy cycles before surgery in people with advanced thymus tumors.
Key facts
- Who runs it
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
- Status
- Not yet recruiting
- Phase
- Phase 2/3
- People taking part
- 116 people, planned
- Started
- Mar 2026
- Expected to end
- Mar 2032
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cyclophosphamide, Doxorubicin, and Cisplatin (CAP)
- nab-Paclitaxel and Carboplatin
- Record updated
- 11 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a thymic epithelial tumor (thymoma or thymic carcinoma). The tumor has grown nearby but may still be removable by surgery. People will get 6 or 3 cycles of chemotherapy before surgery.
- Age
- 18 to 65 years
- Sex
- All sexes
- Disease stage
- Locally advanced disease that may be removable by surgery (Masaoka-Koga stage III or IVA), as judged by a team of specialists. At least one tumor that can be measured on scans (RECIST v1.1). Able to carry out normal daily activities (ECOG 0 or 1).
- Earlier treatment
- No prior anticancer drug treatment for the thymic tumor (no chemotherapy, targeted therapy or immunotherapy). No prior radiation to the chest.
- Biomarker or test result
- Tumor confirmed by tissue or cell testing. Blood tests: neutrophils ≥1.5×10⁹/L, platelets ≥100×10⁹/L, hemoglobin ≥90 g/L; good liver tests; creatinine clearance ≥50 mL/min.
Main reasons for not taking part
- Active autoimmune disease needing whole-body treatment in the past 2 years
- Serious heart problems (NYHA class III or IV heart failure, or LVEF <50%)
- Active hepatitis B or C, or known HIV infection
- Pregnancy or breastfeeding
- Another cancer within 5 years, except some treated skin cancers or cervical carcinoma in situ
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Histologically or cytologically confirmed thymic epithelial tumor (thymoma or thymic carcinoma)
- Locally advanced, potentially resectable disease (Masaoka-Koga stage III or IVA), as evaluated by a multidisciplinary team (MDT) including thoracic surgery and thoracic oncology
- Age 18 to 65 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelet count ≥100×10⁹/L, hemoglobin ≥90 g/L
- Adequate liver function: total bilirubin ≤1.5× upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN
- Adequate renal function: creatinine clearance ≥50 mL/min (Cockcroft-Gault formula)
- No prior systemic anticancer therapy for thymic epithelial tumor
- At least one measurable lesion per RECIST v1.1
- Willing to accept randomization and able to comply with study procedures
- Written informed consent obtained prior to any study-related procedures
Who cannot take part
- Prior chemotherapy, targeted therapy, or immunotherapy for thymic epithelial tumor
- Prior thoracic radiation therapy
- Other malignancy within 5 years prior to enrollment, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix
- Active autoimmune disease requiring systemic treatment within the past 2 years
- Known hypersensitivity or contraindication to study drugs (cisplatin, epirubicin, etoposide, ifosfamide, or any component of these formulations)
- Active hepatitis B (HBsAg positive with HBV DNA ≥2000 IU/mL), active hepatitis C, or known HIV infection
- Uncontrolled active infection requiring systemic therapy
- Any condition that, in the investigator's judgment, would preclude safe participation in the study
- Severe cardiac dysfunction: New York Heart Association (NYHA) class III or IV heart failure, or left ventricular ejection fraction (LVEF) <50%
- Pregnancy or lactation; women of childbearing potential unwilling to use adequate contraception
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized controlled trial compares 6 versus 3 cycles of neoadjuvant chemotherapy in patients with potentially resectable locally advanced thymic epithelial tumors (TETs, WHO type AB/B/C, AJCC TNM stage IIIA-IVA). Patients are randomized 1:1 to receive either 6 or 3 cycles of chemotherapy (cisplatin + doxorubicin + cyclophosphamide for type B; nab-paclitaxel + carboplatin for type C thymoma/thymic carcinoma) every 3 weeks, followed by surgical resection when feasible. The primary endpoint is event-free survival (EFS). The study aims to determine whether extended neoadjuvant chemotherapy improves surgical outcomes and long-term survival in this rare malignancy.
The 2 groups in the trial
- 6-Cycle Neoadjuvant ChemotherapyTreatment being tested
Participants receive 6 cycles of neoadjuvant chemotherapy prior to surgery. For WHO type B thymoma: cyclophosphamide 500 mg/m2 IV + doxorubicin 50 mg/m2 IV + cisplatin 50 mg/m2 IV (CAP regimen), every 3 weeks. For thymic carcinoma: nab-paclitaxel 260 mg/m2 IV + carboplatin AUC 5 IV, every 3 weeks.
Treatment: Cyclophosphamide, Doxorubicin, and Cisplatin (CAP) and nab-Paclitaxel and Carboplatin
- 3-Cycle Neoadjuvant ChemotherapyExisting treatment, for comparison
Participants receive 3 cycles of neoadjuvant chemotherapy prior to surgery. For WHO type B thymoma: cyclophosphamide 500 mg/m2 IV + doxorubicin 50 mg/m2 IV + cisplatin 50 mg/m2 IV (CAP regimen), every 3 weeks. For thymic carcinoma: nab-paclitaxel 260 mg/m2 IV + carboplatin AUC 5 IV, every 3 weeks.
Treatment: Cyclophosphamide, Doxorubicin, and Cisplatin (CAP) and nab-Paclitaxel and Carboplatin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Trial of 6 Versus 3 Cycles of Neoadjuvant Chemotherapy on Event-Free Survival in Patients With Potentially Resectable Locally Advanced Thymic Epithelial Tumors
- Plain-language title
- Comparing 6 and 3 rounds of chemotherapy before surgery for thymus tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT07463313, who can take part
- Record updated
- 11 March 2026